Clinical Trial Update: PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating tislelizumab combined with dacarbazine for advanced melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dacarbazine (dacarbazine)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Advanced Melanoma | Phase 2 | Status: UNKNOWN